Loading clinical trials...

AMG 827 in Subjects With Psoriatic Arthritis | Clinical Trials | Clareo Health

TERMINATEDPHASE2

AMG 827 in Subjects With Psoriatic Arthritis

A Randomized, Double-blinded, Placebo-controlled, Multiple-dose Study With an Open Label Extension to Evaluate the Safety and Efficacy of AMG 827 in Subjects With Psoriatic Arthritis.

NCT01516957•Bausch Health Americas, Inc.

View on ClinicalTrials.gov

Summary

The study will examine the safety and effectiveness of AMG 827 for the treatment of psoriatic arthritis

Detailed Description

The study will examine the safety and effectiveness of AMG 827 for the treatment of psoriatic arthritis. Patients will randomly receive either AMG 827 or placebo (a look-a-like liquid that does not have any drug in it) and neither the doctor nor the patient will know what treatment is being given.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subject has had a diagnosis of psoriatic arthritis (by the Classification of Psoriatic Arthritis (CASPAR) criteria) for at least 6 months
•Subject has ≥ 3 tender and ≥ 3 swollen joints

Exclusion Criteria

•Subject has an active infection or history of infections (systemic anti-infectives were used within 28 days; requiring hospitalization or intravenous anti-infectives within 8 weeks; recurrent or chronic)
•Significant concurrent medical conditions
•Pregnant or breast feeding
•Significant Laboratory abnormalities
•Use of sulfasalazine, hydroxychloroquine, systemically administered calcineurin inhibitors, azathioprine, parenteral corticosteroids including intramuscular or intraarticular administration, or live vaccines within 28 days
•Use of anti-TNF therapy within 2 months
•Use of an anti-interleukin (IL)12/IL-23 drug or other experimental or commercially available biologic therapies for psoriasis and/or psoriatic arthritis within 3 months
•Prior use of rituximab
•Prior use of anti-IL-17 biologic therapy, including AMG 827

Locations (31)

Research Site

Peoria, Arizona, United States

Research Site

Scottsdale, Arizona, United States

Research Site

Tucson, Arizona, United States

Research Site

Hemet, California, United States

Research Site

Huntington Beach, California, United States

Research Site

La Jolla, California, United States

Research Site

Los Angeles, California, United States

Research Site

Palm Desert, California, United States

Research Site

Palo Alto, California, United States

Research Site

Victorville, California, United States

Key Dates

Start Date

October 1, 2011

Primary Completion Date

September 1, 2012

Completion Date

September 1, 2015

Last Updated

August 27, 2020

Enrollment

168

ACTUAL participants

Conditions

Psoriatic Arthritis

Interventions

AMG 827 140

DRUG

Placebo

DRUG

AMG 827 280

DRUG

AMG 827 210

DRUG

A Study of Picankibart in Patients With Active Psoriatic Arthritis

NCT07295509

Psoriatic Arthritis

View study

RECRUITINGPHASE3

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

NCT06100744

Juvenile Psoriatic Arthritis

View study

RECRUITING

Rheumatology Patient Registry and Biorepository

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 27, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

AMG 827 in Subjects With Psoriatic Arthritis

Inclusion Criteria

Exclusion Criteria

A Study of Picankibart in Patients With Active Psoriatic Arthritis

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

Rheumatology Patient Registry and Biorepository

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis

Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis